Envoy Medical, Inc. Form 8-K Summary
Reporting date: June 6, 2024; the filing was signed June 11, 2024. The company is a Delaware medical-device issuer whose Class A common stock trades under “COCH” and whose warrants trade under “COCHW” on Nasdaq.
Business and Reporting Context
The filing reports changes to the company’s board of directors under Item 5.02 and related Regulation FD disclosure under Item 7.01. It does not present quarterly or annual operating results.
Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash-balance, or other financial metrics.
- No financial statements or material financial obligations are reported in the filing.
Material Changes and Corporate Governance
- Dr. Whitney Haring-Smith resigned from the board effective June 6, 2024.
- The filing states that his resignation was not due to a disagreement with the company regarding its operations, policies, or practices.
- On June 7, 2024, the board appointed Michael Crowe to fill the resulting vacancy. Mr. Crowe has extensive medical-device operations experience, including leadership roles at Bioventus and Abbott Vascular.
- Mr. Crowe will receive the standard non-employee director compensation, including $40,000 in annual cash compensation and an option to purchase 25,000 shares of Class A common stock vesting over four years.
- Mr. Crowe will enter into the company’s standard director and officer indemnification agreement. The filing states that there are no special selection arrangements or related-party transactions requiring disclosure under Item 404(a).
Outlook, Risks, and Unusual Items
- No financial guidance, business outlook, forecasts, contingencies, or operating-risk updates are provided.
- The principal disclosed event is the immediate board resignation and replacement.
- The filing references a June 11, 2024 press release announcing the board changes. Regulation FD information, including the press release, is stated not to be deemed “filed” for Section 18 purposes except as expressly incorporated by reference.
Investor Verification Items
- Verify the effective dates: resignation on June 6, appointment on June 7, press release on June 11, and filing signature on June 11.
- Review the company’s latest Form 10-K and subsequent filings for current liquidity, financing needs, operating results, and business risks, none of which are addressed here.
- Confirm the terms and potential dilution associated with Mr. Crowe’s 25,000-share stock option award.
- Review the referenced June 11 press release and the company’s director compensation and indemnification arrangements.